Liver metastases

DI Tsilimigras, P Brodt, PA Clavien… - Nature reviews Disease …, 2021 - nature.com
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

ZF Lim, PC Ma - Journal of hematology & oncology, 2019 - Springer
The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal …

J Watanabe, K Muro, K Shitara, K Yamazaki… - Jama, 2023 - jamanetwork.com
Importance For patients withRASwild-type metastatic colorectal cancer, adding anti–
epidermal growth factor receptor (anti-EGFR) or anti–vascular endothelial growth factor (anti …

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a …

T Powles, ER Plimack, D Soulières, T Waddell… - The Lancet …, 2020 - thelancet.com
Background The first interim analysis of the KEYNOTE-426 study showed superior efficacy
of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced …

[HTML][HTML] Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR …

D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz… - Annals of oncology, 2017 - Elsevier
Background There is increasing evidence that metastatic colorectal cancer (mCRC) is a
genetically heterogeneous disease and that tumours arising from different sides of the colon …

Modern therapeutic approaches for the treatment of malignant liver tumours

H Petrowsky, R Fritsch, M Guckenberger… - Nature reviews …, 2020 - nature.com
Malignant liver tumours include a wide range of primary and secondary tumours. Although
surgery remains the mainstay of curative treatment, modern therapies integrate a variety of …

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type …

S Stintzing, DP Modest, L Rossius, MM Lerch… - The Lancet …, 2016 - thelancet.com
Background FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI)
plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type …

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

V Heinemann, LF von Weikersthal, T Decker… - British journal of …, 2021 - nature.com
Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab
plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no …

Multidisciplinary approach of liver metastases from colorectal cancer

R Adam, Y Kitano - Annals of gastroenterological surgery, 2019 - Wiley Online Library
Colorectal cancer liver metastases (CRLM) represent most of the causes of death in patients
with colorectal cancer. Surgical resection is the only treatment that can provide the …

Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging

L Lu, L Dercle, B Zhao, LH Schwartz - Nature communications, 2021 - nature.com
In current clinical practice, tumor response assessment is usually based on tumor size
change on serial computerized tomography (CT) scan images. However, evaluation of tumor …